Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.33 |
| ▸ | GBA1 | P04062 | 5/20 | 0.32 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DNM2 | P50570 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4940634 | 1.00 | IDO1 (0.38) | IDO1ABCB1GBA1ABCC9GLB1 | |
| SCHEMBL2877822 | 0.89 | IDO1 (0.37) | IDO1ABCB1ABCC9 | |
| Hydrochloric Acid SCHEMBL2873712 | 0.88 | IDO1 (0.37) | IDO1ABCB1ABCC9 | |
| SCHEMBL2011038 | 0.82 | ABCB1 (0.44) | IDO1ABCB1ABCC9 | |
| SCHEMBL12580635 | 0.79 | IDO1 (0.40) | IDO1ABCB1GBA1ABCC9 | |
| Hydrochloric Acid SCHEMBL2883645 | 0.78 | IDO1 (0.39) | IDO1ABCB1GBA1ABCC9GLB1 | |
| Hydrochloric Acid SCHEMBL2883647 | 0.78 | IDO1 (0.39) | IDO1ABCB1GBA1ABCC9GLB1 | |
| SCHEMBL2873106 | 0.77 | ABCC9 (0.37) | ABCB1ABCC9 | |
| SCHEMBL2014393 | 0.77 | ABCC9 (0.37) | ABCB1ABCC9 | |
| SCHEMBL2875990 | 0.76 | IDO1 (0.42) | IDO1ABCB1GBA1ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004262-A1 | Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents | CBR1, CBR3, SCN8A | IDO1 3364/4885ABCB1 580/4885GBA1 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.